-+ 0.00%
-+ 0.00%
-+ 0.00%

Alphabet (GOOGL) Spinout Isomorphic Labs Raised $5 Billion In Series C

Simply Wall St·11/19/2026 18:09:33
Listen to the news
  • Alphabet (NasdaqGS:GOOGL) spinout Isomorphic Labs raised US$5b in a Series C round to fund its AI drug discovery work.
  • The capital will support advancement of Isomorphic Labs' first medicine candidates into clinical trials using its drug design AI platform.
  • This financing underlines Alphabet's ongoing push to apply its AI capabilities to healthcare opportunities beyond advertising and cloud services.
  • Isomorphic Labs' US$5b Series C for AI driven drug discovery is only one piece of the broader Alphabet story. We have also spotted 1 major warning sign worth knowing about at Alphabet.

For readers tracking how AI is reshaping the drug and data supply chain, the next step is to explore 53 AI infrastructure stocks.

NasdaqGS:GOOGL 1-Year Stock Price Chart
NasdaqGS:GOOGL 1-Year Stock Price Chart

Alphabet runs global platforms such as Search, YouTube and Google Cloud, so the push into Isomorphic Labs positions the group to apply its AI research beyond advertising and data services, extending into drug discovery workflows used by healthcare and biopharma clients.

See which insiders are buying and selling Alphabet following this latest news.

How does Isomorphic Labs’ US$5b raise connect back to Alphabet’s AI push?

The funding round signals external investors see commercial potential in Alphabet’s AI drug discovery work, not just its ad and cloud engines. For Alphabet, having a spinout attract US$5b to expand its drug design models and move candidates toward trials reinforces the idea that in house AI research can spawn new, capital backed business lines.

Does this change the Alphabet narrative around AI infrastructure and Cloud?

The analyst narrative already leans on Alphabet turning heavy AI infrastructure and data center spend into profitable Gemini and Google Cloud demand. Isomorphic Labs using that internal AI stack for drug design fits the catalyst of monetizing custom TPUs and AI models across more workloads, while still leaving the core risk that large AI capex must earn attractive paybacks.

See how these catalysts shape Alphabet's path to a $408 fair value.

What should Alphabet investors watch next for this to really move the needle?

The clearest markers will be concrete commercial steps, not just research milestones. That means watching for disclosed licensing deals with big pharma, revenue linked collaborations tied to Isomorphic’s models, or Alphabet commentary that quantifies how much Cloud usage and TPU demand these drug discovery workloads contribute over the next few reporting periods.

One Alphabet thread this article has not pulled yet

Headline figures only tell part of Alphabet’s story, and recent checks on the underlying quality of those reported earnings raise a separate question that deserves its own closer look. See what our checks flag about the quality of Alphabet's earnings.